Mexican Pharma Roundup: February 2020
Below is a selection of top recent news from Mexican pharma and healthcare, including the healthcare reforms president Andres Manuel Lopez Obrador is prioritising, latest news on the INSABI program,…
Patrick is the managing editor of PharmaBoardroom
Below is a selection of top recent news from Mexican pharma and healthcare, including the healthcare reforms president Andres Manuel Lopez Obrador is prioritising, latest news on the INSABI program,…
In 2019, several drug companies testified to the US Senate Finance Committee on medicine price hikes with a narrative of discounts given to health insurance companies and pharmacists, but not…
Growing incidence of lifestyle-related diseases, coupled with high drug prices, are driving up healthcare costs at astounding rates in the Middle East and North Africa, with experts urging preventative measures…
From Turkey to Tajikistan, Bangladesh to Bahrain, and Russia to Rwanda, multinational pharma firms are increasingly situating wide-ranging management responsibilities in the UAE. The following is an inexhaustive list of…
Between 2015 and 2017 PharmaBoardroom met with pharma country managers in Mexico who spoke about the challenges and opportunities present in the Mexican market. Since then, these five stakeholders have…
Below is a selection of the top stories in Indian pharma from recent months, ranging from efforts to counter the coronavirus, to regulatory reform, the spike in USFDA warning letters…
Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019 was still the British industry’s third-best year on record. …
Taiwan, although small in size, boasts a strong culture of innovation as well as a universal healthcare system that is the envy of its neighbours. Here, three country managers for…
In 2019 big pharma companies prioritised shareholder payouts and dividends, with the eight biggest US pharma companies topping $31 billion in stock buybacks and the same amount in dividends. Revenues…
2019 was a bumper year for biotech companies listing on the Hong Kong Exchange (HKEx), with nine pre-revenue biotechs and eight revenue-generating biotech and biotech-related firms, mostly originating from mainland…
With the recent publication of Ten years on: Measuring the Return from Pharmaceutical Innovation 2019, PharmaBoardroom has teamed up with Deloitte to offer its readers an exclusive webinar on The Future of Biopharma. On 25th February…
Puerto Rico had to rebuild itself – in many cases quite literally – after the devastation wrought by Hurricane Maria in 2017. However, despite the havoc that Maria brought to…
See our Cookie Privacy Policy Here
